TRVI

SEC source: 0000950170-25-044436 · ownership.xml · derivative · entry 3

GOOD JENNIFER L · CIK 0001229245 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,263 shares

Expires 2025-05-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: This option was granted on May 15, 2015. The 5,263 shares of common stock underlying the option vested as to 25% of the shares on May 15, 2016 and vested as to the remaining 75% of the shares in equal monthly installments thereafter through May 15, 2019.

SEC source: 0000950170-25-044436 · ownership.xml · nonDerivative · entry 2

GOOD JENNIFER L · CIK 0001229245 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 213,313

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.55 to $6.60 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0000950170-25-044436 · ownership.xml · nonDerivative · entry 1

GOOD JENNIFER L · CIK 0001229245 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 218,576

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000950170-25-037882 · ownership.xml · derivative · entry 1

Galletta Christopher · CIK 0001486099 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,560

Underlying: Common Stock · 4,560 shares

Expires 2034-02-14

F1 · shares: Reporting person was granted a performance-based stock option on February 15, 2024, to purchase 14,250 shares of common stock. The option vests based on the attainment of established performance criteria related to the timing and successful results of the Company's Phase 2b CORAL trial of Haduvio (nalbuphine ER) in patients with chronic cough in idiopathic pulmonary fibrosis, and Phase 2 RIVER trial of Haduvio in patients with refractory chronic cough. On March 10, 2025, the Compensation Committee of the Board of Directors of the Issuer certified that the performance metrics related to the successful results of the RIVER trial were satisfied, resulting in the vesting of the option as to 4,560 shares of common stock. The performance-based stock option remains eligible for vesting with respect to additional shares of common stock underlying the option in the event that performance metrics related to the successful results of the CORAL trial are satisfied.

SEC source: 0000950170-25-037883 · ownership.xml · derivative · entry 1

SCIASCIA THOMAS · CIK 0001229946 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,000

Underlying: Common Stock · 32,000 shares

Expires 2034-02-14

F1 · shares: Reporting person was granted a performance-based stock option on February 15, 2024, to purchase 100,000 shares of common stock. The option vests based on the attainment of established performance criteria related to the timing and successful results of the Company's Phase 2b CORAL trial of Haduvio (nalbuphine ER) in patients with chronic cough in idiopathic pulmonary fibrosis, and Phase 2 RIVER trial of Haduvio in patients with refractory chronic cough. On March 10, 2025, the Compensation Committee of the Board of Directors of the Issuer certified that the performance metrics related to the successful results of the RIVER trial were satisfied, resulting in the vesting of the option as to 32,000 shares of common stock. The performance-based stock option remains eligible for vesting with respect to additional shares of common stock underlying the option in the event that performance metrics related to the successful results of the CORAL trial are satisfied.

SEC source: 0000950170-25-037886 · ownership.xml · derivative · entry 1

GOOD JENNIFER L · CIK 0001229245 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 54,400

Underlying: Common Stock · 54,400 shares

Expires 2034-02-14

F1 · shares: Reporting person was granted a performance-based stock option on February 15, 2024, to purchase 170,000 shares of common stock. The option vests based on the attainment of established performance criteria related to the timing and successful results of the Company's Phase 2b CORAL trial of Haduvio (nalbuphine ER) in patients with chronic cough in idiopathic pulmonary fibrosis, and Phase 2 RIVER trial of Haduvio in patients with refractory chronic cough. On March 10, 2025, the Compensation Committee of the Board of Directors of the Issuer certified that the performance metrics related to the successful results of the RIVER trial were satisfied, resulting in the vesting of the option as to 54,400 shares of common stock. The performance-based stock option remains eligible for vesting with respect to additional shares of common stock underlying the option in the event that performance metrics related to the successful results of the CORAL trial are satisfied.

SEC source: 0000950170-25-037880 · ownership.xml · derivative · entry 9

Simon Farrell · CIK 0001965585 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 18,750

Underlying: Common Stock · 31,250 shares

Expires 2032-02-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F8 · derivative.exercise_date: This option was granted on February 11, 2022. The 75,000 shares of common stock underlying the option vested as to 25% of the shares on February 11, 2023 and vest as to the remaining 75% of the shares in equal monthly installments thereafter through February 11, 2026.

SEC source: 0000950170-25-037880 · ownership.xml · derivative · entry 8

Simon Farrell · CIK 0001965585 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 11,187

Underlying: Common Stock · 63,813 shares

Expires 2030-09-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_date: This option was granted on September 22, 2020. The 75,000 shares of common stock underlying the option vested as to 25% of the shares on September 22, 2021 and vested as to the remaining 75% of the shares in equal monthly installments thereafter through September 22, 2024.

SEC source: 0000950170-25-037880 · ownership.xml · derivative · entry 7

Simon Farrell · CIK 0001965585 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 17,500 shares

Expires 2031-02-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: Reporting person was granted a performance-based stock option on February 17, 2021, to purchase 17,500 shares of common stock. The option vested based on the attainment of established performance criteria related to the timing and successful results of the Company's Phase 2b/3 PRISM trial of Haduvio for the treatment of prurigo nodularis, and Phase 2 CANAL trial of Haduvio for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis.

SEC source: 0000950170-25-037880 · ownership.xml · derivative · entry 6

Simon Farrell · CIK 0001965585 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 38,400

Underlying: Common Stock · 38,400 shares

Expires 2034-02-14

F5 · shares: Reporting person was granted a performance-based stock option on February 15, 2024, to purchase 120,000 shares of common stock. The option vests based on the attainment of established performance criteria related to the timing and successful results of the Company's Phase 2b CORAL trial of Haduvio (nalbuphine ER) in patients with chronic cough in idiopathic pulmonary fibrosis, and Phase 2 RIVER trial of Haduvio in patients with refractory chronic cough. On March 10, 2025, the Compensation Committee of the Board of Directors of the Issuer certified that the performance metrics related to the successful results of the RIVER trial were satisfied, resulting in the vesting of the option as to 38,400 shares of common stock. The performance-based stock option remains eligible for vesting with respect to additional shares of common stock underlying the option in the event that performance metrics related to the successful results of the CORAL trial are satisfied.

SEC source: 0000950170-25-037880 · ownership.xml · nonDerivative · entry 5

Simon Farrell · CIK 0001965585 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 76,900

F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan that was adopted on April 9, 2024.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.14 to $7.16 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0000950170-25-037880 · ownership.xml · nonDerivative · entry 4

Simon Farrell · CIK 0001965585 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 81,250

F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan that was adopted on April 9, 2024.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.14 to $7.13 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0000950170-25-037880 · ownership.xml · nonDerivative · entry 3

Simon Farrell · CIK 0001965585 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 158,213

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This exercise of stock options was effected pursuant to a Rule 10b5-1 trading plan that was adopted on April 9, 2024.

SEC source: 0000950170-25-037880 · ownership.xml · nonDerivative · entry 2

Simon Farrell · CIK 0001965585 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 126,963

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This exercise of stock options was effected pursuant to a Rule 10b5-1 trading plan that was adopted on April 9, 2024.

SEC source: 0000950170-25-037880 · ownership.xml · nonDerivative · entry 1

Simon Farrell · CIK 0001965585 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 63,150

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This exercise of stock options was effected pursuant to a Rule 10b5-1 trading plan that was adopted on April 9, 2024.

SEC source: 0000950170-25-037884 · ownership.xml · derivative · entry 1

Delfini Lisa · CIK 0001873253 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 38,400

Underlying: Common Stock · 38,400 shares

Expires 2034-02-14

F1 · shares: Reporting person was granted a performance-based stock option on February 15, 2024, to purchase 120,000 shares of common stock. The option vests based on the attainment of established performance criteria related to the timing and successful results of the Company's Phase 2b CORAL trial of Haduvio (nalbuphine ER) in patients with chronic cough in idiopathic pulmonary fibrosis, and Phase 2 RIVER trial of Haduvio in patients with refractory chronic cough. On March 10, 2025, the Compensation Committee of the Board of Directors of the Issuer certified that the performance metrics related to the successful results of the RIVER trial were satisfied, resulting in the vesting of the option as to 38,400 shares of common stock. The performance-based stock option remains eligible for vesting with respect to additional shares of common stock underlying the option in the event that performance metrics related to the successful results of the CORAL trial are satisfied.

SEC source: 0000950170-25-024109 · ownership.xml · derivative · entry 1

Galletta Christopher · CIK 0001486099 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,000

Underlying: Common Stock · 41,000 shares

Expires 2035-02-17

F1 · derivative.exercise_date: This option was granted on February 18, 2025. The 41,000 shares of common stock underlying the option are scheduled to vest as to 25% of the shares on February 18, 2026 and as to the remaining 75% of the shares in equal monthly installments thereafter through February 18, 2029.

SEC source: 0000950170-25-024116 · ownership.xml · derivative · entry 1

Cassella James V · CIK 0001353528 · Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 257,500

Underlying: Common Stock · 257,500 shares

Expires 2035-02-17

F1 · derivative.exercise_date: This option was granted on February 18, 2025. The 257,500 shares of common stock underlying the option are scheduled to vest as to 25% of the shares on February 18, 2026 and as to the remaining 75% of the shares in equal monthly installments thereafter through February 18, 2029.

SEC source: 0000950170-25-024117 · ownership.xml · derivative · entry 1

SCIASCIA THOMAS · CIK 0001229946 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 116,000

Underlying: Common Stock · 116,000 shares

Expires 2035-02-17

F1 · derivative.exercise_date: This option was granted on February 18, 2025. The 116,000 shares of common stock underlying the option are scheduled to vest as to 25% of the shares on February 18, 2026 and as to the remaining 75% of the shares in equal monthly installments thereafter through February 18, 2029.

SEC source: 0000950170-25-024110 · ownership.xml · derivative · entry 1

GOOD JENNIFER L · CIK 0001229245 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 811,000

Underlying: Common Stock · 811,000 shares

Expires 2035-02-17

F1 · derivative.exercise_date: This option was granted on February 18, 2025. The 811,000 shares of common stock underlying the option are scheduled to vest as to 25% of the shares on February 18, 2026 and as to the remaining 75% of the shares in equal monthly installments thereafter through February 18, 2029.

SEC source: 0000950170-25-024111 · ownership.xml · derivative · entry 1

Delfini Lisa · CIK 0001873253 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 225,500

Underlying: Common Stock · 225,500 shares

Expires 2035-02-17

F1 · derivative.exercise_date: This option was granted on February 18, 2025. The 225,500 shares of common stock underlying the option are scheduled to vest as to 25% of the shares on February 18, 2026 and as to the remaining 75% of the shares in equal monthly installments thereafter through February 18, 2029.

SEC source: 0000950170-25-024114 · ownership.xml · derivative · entry 1

Simon Farrell · CIK 0001965585 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 225,500

Underlying: Common Stock · 225,500 shares

Expires 2035-02-17

F1 · derivative.exercise_date: This option was granted on February 18, 2025. The 225,500 shares of common stock underlying the option are scheduled to vest as to 25% of the shares on February 18, 2026 and as to the remaining 75% of the shares in equal monthly installments thereafter through February 18, 2029.

SEC source: 0000950170-25-004164 · ownership.xml · derivative · entry 4

Delfini Lisa · CIK 0001873253 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 42,125

Underlying: Common Stock · 5,000 shares

Expires 2032-02-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: This option was granted on February 11, 2022. The 110,000 shares of common stock underlying the option vested as to 25% of the shares on February 11, 2023 and vest as to the remaining 75% of the shares in equal monthly installments thereafter through February 11, 2026.

SEC source: 0000950170-25-004164 · ownership.xml · nonDerivative · entry 2

Delfini Lisa · CIK 0001873253 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 64,660

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000950170-25-004164 · ownership.xml · derivative · entry 3

Delfini Lisa · CIK 0001873253 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 47,125

Underlying: Common Stock · 1,000 shares

Expires 2032-02-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: This option was granted on February 11, 2022. The 110,000 shares of common stock underlying the option vested as to 25% of the shares on February 11, 2023 and vest as to the remaining 75% of the shares in equal monthly installments thereafter through February 11, 2026.

SEC source: 0000950170-25-004164 · ownership.xml · nonDerivative · entry 1

Delfini Lisa · CIK 0001873253 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 59,660

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 5,381 shares purchased through the Issuer's employee stock purchase plan.

SEC source: 0000950170-24-137255 · ownership.xml · derivative · entry 2

Galletta Christopher · CIK 0001486099 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 15,000 shares

Expires 2032-02-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: This option was granted on February 11, 2022. The 35,000 shares of common stock underlying the option vested as to 25% of the shares on February 11, 2023 and vest as to the remaining 75% of the shares in equal monthly installments thereafter through February 11, 2026.

SEC source: 0000950170-24-137255 · ownership.xml · nonDerivative · entry 1

Galletta Christopher · CIK 0001486099 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,935

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 4,935 shares purchased through the Issuer's employee stock purchase plan.

SEC source: 0000950170-24-110921 · ownership.xml · derivative · entry 1

Cassella James V · CIK 0001353528 · Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 400,000

Underlying: Common Stock · 400,000 shares

Expires 2034-09-29

F1 · derivative.exercise_date: This option was granted on September 30, 2024. The 400,000 shares of common stock underlying the option are scheduled to vest as to 25% of the shares on September 30, 2025 and as to the remaining 75% of the shares in equal monthly installments thereafter, through September 30, 2028.

SEC source: 0000950170-24-104804 · ownership.xml · derivative · entry 6

GOOD JENNIFER L · CIK 0001229245 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,840 shares

Expires 2024-11-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: This option was granted on November 25, 2014. The 61,180 shares of common stock underlying the option vested as to 25% of the shares on November 25, 2015 and vested as to the remaining 75% of the shares in equal monthly installments thereafter through November 25, 2018.

SEC source: 0000950170-24-104804 · ownership.xml · nonDerivative · entry 4

GOOD JENNIFER L · CIK 0001229245 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 213,313

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.010 to $3.085 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0000950170-24-104804 · ownership.xml · nonDerivative · entry 3

GOOD JENNIFER L · CIK 0001229245 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 215,153

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000950170-24-104804 · ownership.xml · derivative · entry 5

GOOD JENNIFER L · CIK 0001229245 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,840

Underlying: Common Stock · 4,219 shares

Expires 2024-11-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: This option was granted on November 25, 2014. The 61,180 shares of common stock underlying the option vested as to 25% of the shares on November 25, 2015 and vested as to the remaining 75% of the shares in equal monthly installments thereafter through November 25, 2018.

SEC source: 0000950170-24-104804 · ownership.xml · nonDerivative · entry 2

GOOD JENNIFER L · CIK 0001229245 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 213,313

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.00 to $3.10 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0000950170-24-104804 · ownership.xml · nonDerivative · entry 1

GOOD JENNIFER L · CIK 0001229245 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 217,532

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000950170-24-104061 · ownership.xml · derivative · entry 9

GOOD JENNIFER L · CIK 0001229245 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,059

Underlying: Common Stock · 40,277 shares

Expires 2024-11-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: This option was granted on November 25, 2014. The 61,180 shares of common stock underlying the option vested as to 25% of the shares on November 25, 2015 and vested as to the remaining 75% of the shares in equal monthly installments thereafter through November 25, 2018.

SEC source: 0000950170-24-104061 · ownership.xml · nonDerivative · entry 6

GOOD JENNIFER L · CIK 0001229245 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 213,313

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.05 to $3.18 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0000950170-24-104061 · ownership.xml · nonDerivative · entry 5

GOOD JENNIFER L · CIK 0001229245 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 253,590

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000950170-24-104061 · ownership.xml · derivative · entry 8

GOOD JENNIFER L · CIK 0001229245 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 46,336

Underlying: Common Stock · 10,981 shares

Expires 2024-11-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: This option was granted on November 25, 2014. The 61,180 shares of common stock underlying the option vested as to 25% of the shares on November 25, 2015 and vested as to the remaining 75% of the shares in equal monthly installments thereafter through November 25, 2018.

SEC source: 0000950170-24-104061 · ownership.xml · nonDerivative · entry 4

GOOD JENNIFER L · CIK 0001229245 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 213,313

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.02 to $3.11 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0000950170-24-104061 · ownership.xml · nonDerivative · entry 3

GOOD JENNIFER L · CIK 0001229245 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 224,294

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000950170-24-104061 · ownership.xml · derivative · entry 7

GOOD JENNIFER L · CIK 0001229245 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 57,317

Underlying: Common Stock · 3,863 shares

Expires 2024-11-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: This option was granted on November 25, 2014. The 61,180 shares of common stock underlying the option vested as to 25% of the shares on November 25, 2015 and vested as to the remaining 75% of the shares in equal monthly installments thereafter through November 25, 2018.

SEC source: 0000950170-24-104061 · ownership.xml · nonDerivative · entry 2

GOOD JENNIFER L · CIK 0001229245 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 213,313

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.01 to $3.03 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0000950170-24-104061 · ownership.xml · nonDerivative · entry 1

GOOD JENNIFER L · CIK 0001229245 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 217,176

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000950170-24-101926 · ownership.xml · derivative · entry 3

Meeker David P · CIK 0001385155 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 4,555 shares

Expires 2024-11-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: This option was granted on November 25, 2014. The 4,555 shares of common stock underlying the option vested as to 25% of the shares on November 25, 2015 and vested as to the remaining 75% of the shares in equal quarterly installments thereafter through November 25, 2018.

SEC source: 0000950170-24-101926 · ownership.xml · nonDerivative · entry 2

Meeker David P · CIK 0001385155 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 352,489

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.9100 to $2.9500 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0000950170-24-101926 · ownership.xml · nonDerivative · entry 1

Meeker David P · CIK 0001385155 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 357,044

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000950170-24-099481 · ownership.xml · derivative · entry 3

SCIASCIA THOMAS · CIK 0001229946 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 16,496 shares

Expires 2024-11-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: This option was granted on November 25, 2014. The 48,001 shares of common stock underlying the option vested as to 25% of the shares on November 25, 2015 and vested as to the remaining 75% of the shares in equal monthly installments thereafter through November 25, 2018.

SEC source: 0000950170-24-099481 · ownership.xml · nonDerivative · entry 2

SCIASCIA THOMAS · CIK 0001229946 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 220,315

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.9000 to $3.0020 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0000950170-24-099481 · ownership.xml · nonDerivative · entry 1

SCIASCIA THOMAS · CIK 0001229946 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 236,811

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.